Claris Lifesciences gains on receiving USFDA approval for finished dosage and API plants

09 Jul 2014 Evaluate

Claris Lifesciences is currently trading at Rs. 173.00, up by 9.80 points or 6.00% from its previous closing of Rs. 163.20 on the BSE.

The scrip opened at Rs. 175.00 and has touched a high and low of Rs. 175.05 and Rs. 170.00 respectively. So far 64,000 shares were traded on the counter.

The BSE group 'B ' stock of face value Rs. 10 has touched a 52 week high of Rs. 229.00 on 30-Dec-2013 and a 52 week low of Rs. 141.25 on 02-Jun-2014.

Last one week high and low of the scrip stood at Rs. 175.05 and Rs. 157.65 respectively. The current market cap of the company is Rs. 1,103.00 crore.

The promoters holding in the company stood at 60.21%, while Institutions and Non-Institutions held 24.71% and 15.08% respectively.

Claris Lifesciences has received a report from US Food and Drug Administration (USFDA) for the inspection it conducted classifying the finished dosage plant and API plant as acceptable.

Claris Lifesciences is one of the few injectables companies in India to have its own front end in the US, the company markets its products through its wholly owned subsidiary Claris Lifesciences Inc. The company now has 11 ANDAs approved and has a total filing of 32 ANDAs.

Peers
Company Name CMP
Redington 263.55
Adani Enterprises 2156.70
Amrapali Industries 14.50
Rashi Peripheral 368.00
PDS 347.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×